JMP Securities Increases Arbutus Biopharma (NASDAQ:ABUS) Price Target to $5.00

Arbutus Biopharma (NASDAQ:ABUS) had its price target lifted by JMP Securities to $5.00 in a report published on Wednesday,Stock Target Advisor reports. JMP Securities currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently issued reports on ABUS. Jefferies Financial Group raised their price objective on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. StockNews.com upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.38.

Arbutus Biopharma Stock Up 0.5 %

Shares of NASDAQ:ABUS opened at $3.75 on Wednesday. The company has a market cap of $707.93 million, a price-to-earnings ratio of -8.72 and a beta of 1.92. The business has a 50 day moving average price of $4.03 and a 200 day moving average price of $3.58. Arbutus Biopharma has a twelve month low of $1.70 and a twelve month high of $4.72.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. nVerses Capital LLC bought a new stake in Arbutus Biopharma in the 2nd quarter valued at $34,000. Walleye Trading LLC bought a new position in shares of Arbutus Biopharma during the 1st quarter worth about $36,000. Helen Stephens Group LLC acquired a new stake in shares of Arbutus Biopharma during the 3rd quarter valued at about $50,000. XTX Topco Ltd bought a new stake in Arbutus Biopharma in the second quarter valued at about $53,000. Finally, Price T Rowe Associates Inc. MD raised its position in Arbutus Biopharma by 22.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 6,649 shares in the last quarter. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.